Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + envafolimab + mFOLFOXIRI
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy regimen consisting of cetuximab (an EGFR inhibitor monoclonal antibody), envafolimab (an immune checkpoint inhibitor), and mFOLFOXIRI (a modified chemotherapy regimen containing oxaliplatin, irinotecan, folinic acid, and 5-fluorouracil). This combination likely targets multiple pathways in cancer treatment, including EGFR signaling, immune checkpoint inhibition, and DNA synthesis disruption.
02
Targets
TOP1 (DNA Topoisomerase I)EGFR (Epidermal growth factor receptor)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)
Beyond the preview
Go deeper on cetuximab + envafolimab + mFOLFOXIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + envafolimab + mFOLFOXIRI.